SLC5A2 and chronic kidney disease: According to clinical trial data, including findings from DAPA-HF, DAPA-CKD, DELIVER [22], and EMPA-KIDNEY [23], the indications for SGLT2 inhibitors have been expanded to encompass HF and CKD [24].